|
|
|
|
|
by jjcon
1905 days ago
|
|
I think the idea is that biontechs contribution is a dime a dozen at this point - the heavy lifting (ie where demand outstrips supply) is being done by Pfizer not biontech If this were not the case why is it that the EU vaccine rollout has been dismal compared to the US and UK? It’s because they don’t have the negotiating power that comes with having what is actually in demand - production capacity. |
|
Because both do not export any vaccine. And the EU does. So even Canada cannot get vaccines from the US and gets it from the EU which exported about half its production outside the EU. Some even went to the US.
Partnering with Pfizer was done because the BioNtech CEO knew people at Pfizer from before. If they would’ve chosen e.g. Bayer (which is what CureVac did) the story of would’ve been different.